Objective This study aimed to evaluate the clinical efficacy of Jia Wei Shoutai Wan (JWSTW) combined with dydrogesterone in patients with threatened abortion (TA) complicated by endometrial cavity fluid (ECF). Methods This was a prospective, single‐center, randomized controlled trial. A total of 130 patients with TA and ECF admitted to our hospital from January to November 2022 were screened. Thirteen patients did not meet the inclusion criteria, and five refused to participate, leaving 112 eligible participants. Using a random number table, patients were assigned to a control group (dydrogesterone alone, n = 56) or a combination group (dydrogesterone plus JWSTW, n = 56). Both groups received continuous treatment for 14 days. During follow‐up, 3 patients withdrew and 6 were excluded, resulting in 103 cases included in the final analysis (control group, n = 50; combination group, n = 53). The primary outcomes were ECF area and Traditional Chinese Medicine (TCM) syndrome scores (vaginal bleeding, lower abdominal pain, fatigue and tiredness, knee soreness, and lumbago) after 14 days of treatment. Secondary outcomes included serum levels of progesterone (P), β‐human chorionic gonadotropin (β‐HCG), and estradiol (E2); coagulation indices D‐dimer (D‐D), fibrinogen (FIB), and prothrombin time (PT); clinical efficacy; and adverse reactions. Results After treatment, the combination group showed significantly lower TCM symptom scores and a smaller ECF area ( p < 0.05). Serum levels of P, β‐HCG, and E2 were higher in the combination group, while D‐D and FIB levels were lower and PT was longer compared with the control group ( p < 0.05). Adverse reactions were monitored, including premature rupture of membranes, postpartum hemorrhage, placental adhesion, preterm delivery, and placenta previa. The total incidence was 8.00% in the control group (4/50) and 3.77% in the combination group (2/53), with no statistically significant difference between the groups ( p = 0.360). The overall clinical efficacy of the combination group was superior to that of the control group ( p < 0.05). Conclusion JWSTW combined with dydrogesterone may be beneficial for treating TA with ECF by improving clinical symptoms, optimizing hormone and coagulation profiles, and reducing ECF without increasing adverse reactions.
Zhang et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: